576 related articles for article (PubMed ID: 23866703)
1. [Effects of exogenous interleukin-2, interleukin-23 on differentiation of IRBP 1-20-specific T cells toward Th1 and Th17 and comparison of the pathogenicity of IRBP 1-20-specific T cells].
Li Y; Cui Y; Bi HS; Wang Y; Li J; Wang XR
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):224-9. PubMed ID: 23866703
[TBL] [Abstract][Full Text] [Related]
2. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
3. [Regulation of antigen specific Th17 cells differentiation in experimental autoimmune uveitis].
Chen HT; Wang H; Zhao M; Hou B
Zhonghua Yan Ke Za Zhi; 2012 Mar; 48(3):234-40. PubMed ID: 22800421
[TBL] [Abstract][Full Text] [Related]
4. [Effects of leflunomide on experimental autoimmune uveitis in Lewis rats].
Fang C; Zhou D; Zhan S; He Y; Lin Z; Huang C; Li J
Zhonghua Yan Ke Za Zhi; 2015 Oct; 51(10):754-61. PubMed ID: 26693771
[TBL] [Abstract][Full Text] [Related]
5. SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU).
Vistica BP; Shi G; Nugent L; Tan C; Altman A; Gery I
Mol Vis; 2012; 18():1858-64. PubMed ID: 22815639
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis.
Takeuchi M; Yokoi H; Tsukahara R; Sakai J; Usui M
Jpn J Ophthalmol; 2001; 45(5):463-9. PubMed ID: 11583666
[TBL] [Abstract][Full Text] [Related]
7. Invariant NKT cells regulate experimental autoimmune uveitis through inhibition of Th17 differentiation.
Oh K; Byoun OJ; Ham DI; Kim YS; Lee DS
Eur J Immunol; 2011 Feb; 41(2):392-402. PubMed ID: 21268009
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
9. Regulation of interphotoreceptor retinoid-binding protein (IRBP)-specific Th1 and Th17 cells in anterior chamber-associated immune deviation (ACAID).
Cui Y; Shao H; Sun D; Kaplan HJ
Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5811-7. PubMed ID: 19458338
[TBL] [Abstract][Full Text] [Related]
10. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
11. Leucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response.
Wandu WS; Tan C; Ogbeifun O; Vistica BP; Shi G; Hinshaw SJ; Xie C; Chen X; Klinman DM; Cai H; Gery I
PLoS One; 2015; 10(6):e0128906. PubMed ID: 26067490
[TBL] [Abstract][Full Text] [Related]
12. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
13. Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis.
Peng Y; Han G; Shao H; Wang Y; Kaplan HJ; Sun D
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4153-61. PubMed ID: 17724201
[TBL] [Abstract][Full Text] [Related]
14. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.
Keino H; Watanabe T; Sato Y; Niikura M; Wada Y; Okada AA
Arthritis Res Ther; 2008; 10(5):R122. PubMed ID: 18847496
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis.
Keino H; Watanabe T; Sato Y; Okada AA
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1548-56. PubMed ID: 20861477
[TBL] [Abstract][Full Text] [Related]
17. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells.
Bing SJ; Lyu C; Xu B; Wandu WS; Hinshaw SJ; Furumoto Y; Caspi RR; Gadina M; Gery I
Mol Vis; 2020; 26():641-651. PubMed ID: 33088168
[TBL] [Abstract][Full Text] [Related]
20. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Kwak HJ; Yang YS; Pae HO; Kim YM; Chung HT
Mol Cells; 2001 Oct; 12(2):178-84. PubMed ID: 11710518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
